A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis

Clinical Nephrology

Volumn 68, Issue 6, 2007, Pages 386-391

  Delmez, J ^a   Block, G ^b   Robertson, J ^c   Chasan Taber, S ^d   Blair, A ^d   Dillon, M ^d   Bleyer, A J ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Denver Nephrologists   (United States)

^c Apex Research of Riverside   (United States)

^d GENZYME CORPORATION   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bicarbonate; Hemodialysis; Phosphorus; Sevelamer carbonate; Sevelamer hydrochloride

Indexed keywords

ANION EXCHANGE RESIN; BICARBONATE; CALCIUM; CHOLESTEROL; CINACALCET; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; RENVELA; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BICARBONATE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT DURATION; VOMITING;

EID: 37149001458     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68386     Document Type: Article

References (13)

1. Asmus HG, Braun J, Krause R et al. Two-year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005; 20: 1653-1661.
2. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999; 33: 694-701.
3. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
4. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-441.
5. Bommner J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate level with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44: 661-671.
6. Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. 1999; 14: 2907-2914.
7. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney hit. 2002; 62: 245-252.
8. Kalantar-Zadeh K, Mehrotra R, Fouque D et al. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial. 2004; 17: 455-465.
9. Kraut JA. The role ofmetabolic acidosis in the pathogenesis of renal osteodystrophy. Adv Ren Replace Ther. 1995; 2: 40-51.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidermas in chronic kidney disease. Am J Kidney Dis. 2003; 41 (Suppl 3): S1-S91.
11. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999; 55: 299-307.
12. Vernejoul MC, Gueris J, Goldfarb B et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney bit. 1989; 36: 1112-1118.
13. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.